OVERVIEW

Reducing Treatment Burden in Neovascular Age-related Macular Degeneration: What's Now? What's Next? is organized by Paradigm Medical Communications, LLC.

Dates:
Release Date: September 14, 2018
Last Reviewed: June 28, 2019
Expiration Date: September 14, 2019

Target Audience
This activity is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists. It may also be of benefit to other clinicians treating patients with neovascular age-related macular degeneration (nAMD).

Statement of Need:
Neovascular, or “wet” age-related macular degeneration (nAMD) imposes a high burden on patients and eye care providers alike, as optimal visual outcomes have been contingent on regular (often monthly), ongoing treatment, typically with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. This educational webinar will acquaint retina specialists and comprehensive ophthalmologists with new and anxiously awaited treatments and strategies that have the potential to reduce nAMD treatment burden, while maintaining (and possibly enhancing) the long-term visual outcomes and safety associated with conventional dosing protocols and treatments. This activity will also explore both in-office diagnostics and home-based patient tools that can be used to aid early diagnosis, so that treatment can be initiated as soon as possible for optimal visual outcomes.

Learning Objectives:
Upon proper completion of this activity, participants should be better able to:
• Identify early signs of neovascular age-related macular degeneration based on recommended tests.
• Apply evidence informing the use of dosing strategies for current intravitreal anti-VEGF agents that have been proven to reduce treatment burden without sacrificing long-term visual outcomes in patients with neovascular age-related macular degeneration.
• Differentiate new and emerging agents and modalities for neovascular age-related macular degeneration, based on clinical profile, mechanism of action, pharmacology, dosing, and delivery, as appropriate.